184 related articles for article (PubMed ID: 28993412)
1. IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.
Lamichhane P; Karyampudi L; Shreeder B; Krempski J; Bahr D; Daum J; Kalli KR; Goode EL; Block MS; Cannon MJ; Knutson KL
Cancer Res; 2017 Dec; 77(23):6667-6678. PubMed ID: 28993412
[TBL] [Abstract][Full Text] [Related]
2. Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.
Alexander ET; Minton AR; Peters MC; van Ryn J; Gilmour SK
Oncotarget; 2016 Dec; 7(51):85291-85305. PubMed ID: 27852034
[TBL] [Abstract][Full Text] [Related]
3. Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer.
Gopinathan G; Berlato C; Lakhani A; Szabova L; Pegrum C; Pedrosa AR; Laforets F; Maniati E; Balkwill FR
Mol Cancer Ther; 2022 Jun; 21(6):1030-1043. PubMed ID: 35313341
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.
Scarlett UK; Rutkowski MR; Rauwerdink AM; Fields J; Escovar-Fadul X; Baird J; Cubillos-Ruiz JR; Jacobs AC; Gonzalez JL; Weaver J; Fiering S; Conejo-Garcia JR
J Exp Med; 2012 Mar; 209(3):495-506. PubMed ID: 22351930
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.
Maj T; Wang W; Crespo J; Zhang H; Wang W; Wei S; Zhao L; Vatan L; Shao I; Szeliga W; Lyssiotis C; Liu JR; Kryczek I; Zou W
Nat Immunol; 2017 Dec; 18(12):1332-1341. PubMed ID: 29083399
[TBL] [Abstract][Full Text] [Related]
6. Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.
Kumar V; Donthireddy L; Marvel D; Condamine T; Wang F; Lavilla-Alonso S; Hashimoto A; Vonteddu P; Behera R; Goins MA; Mulligan C; Nam B; Hockstein N; Denstman F; Shakamuri S; Speicher DW; Weeraratna AT; Chao T; Vonderheide RH; Languino LR; Ordentlich P; Liu Q; Xu X; Lo A; Puré E; Zhang C; Loboda A; Sepulveda MA; Snyder LA; Gabrilovich DI
Cancer Cell; 2017 Nov; 32(5):654-668.e5. PubMed ID: 29136508
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-10-regulated tumour tolerance in non-small cell lung cancer.
Vahl JM; Friedrich J; Mittler S; Trump S; Heim L; Kachler K; Balabko L; Fuhrich N; Geppert CI; Trufa DI; Sopel N; Rieker R; Sirbu H; Finotto S
Br J Cancer; 2017 Nov; 117(11):1644-1655. PubMed ID: 29016555
[TBL] [Abstract][Full Text] [Related]
8. CCR5
Blattner C; Fleming V; Weber R; Himmelhan B; Altevogt P; Gebhardt C; Schulze TJ; Razon H; Hawila E; Wildbaum G; Utikal J; Karin N; Umansky V
Cancer Res; 2018 Jan; 78(1):157-167. PubMed ID: 29089297
[TBL] [Abstract][Full Text] [Related]
9. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Gettinger S; Choi J; Hastings K; Truini A; Datar I; Sowell R; Wurtz A; Dong W; Cai G; Melnick MA; Du VY; Schlessinger J; Goldberg SB; Chiang A; Sanmamed MF; Melero I; Agorreta J; Montuenga LM; Lifton R; Ferrone S; Kavathas P; Rimm DL; Kaech SM; Schalper K; Herbst RS; Politi K
Cancer Discov; 2017 Dec; 7(12):1420-1435. PubMed ID: 29025772
[TBL] [Abstract][Full Text] [Related]
10. Ascites-derived IL-6 and IL-10 synergistically expand CD14
Wu L; Deng Z; Peng Y; Han L; Liu J; Wang L; Li B; Zhao J; Jiao S; Wei H
Oncotarget; 2017 Sep; 8(44):76843-76856. PubMed ID: 29100353
[TBL] [Abstract][Full Text] [Related]
11. Next generation of immune checkpoint therapy in cancer: new developments and challenges.
Marin-Acevedo JA; Dholaria B; Soyano AE; Knutson KL; Chumsri S; Lou Y
J Hematol Oncol; 2018 Mar; 11(1):39. PubMed ID: 29544515
[TBL] [Abstract][Full Text] [Related]
12. Targeting myeloid cells in the tumor sustaining microenvironment.
Schupp J; Krebs FK; Zimmer N; Trzeciak E; Schuppan D; Tuettenberg A
Cell Immunol; 2019 Sep; 343():103713. PubMed ID: 29129292
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of TAP1 and TAP2 in early stage breast cancer.
Henle AM; Nassar A; Puglisi-Knutson D; Youssef B; Knutson KL
PLoS One; 2017; 12(11):e0187323. PubMed ID: 29091951
[TBL] [Abstract][Full Text] [Related]
14. Bacterially activated B-cells drive T cell differentiation towards Tr1 through PD-1/PD-L1 expression.
Said SS; Barut GT; Mansur N; Korkmaz A; Sayi-Yazgan A
Mol Immunol; 2018 Apr; 96():48-60. PubMed ID: 29494848
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.
Stone ML; Chiappinelli KB; Li H; Murphy LM; Travers ME; Topper MJ; Mathios D; Lim M; Shih IM; Wang TL; Hung CF; Bhargava V; Wiehagen KR; Cowley GS; Bachman KE; Strick R; Strissel PL; Baylin SB; Zahnow CA
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10981-E10990. PubMed ID: 29203668
[TBL] [Abstract][Full Text] [Related]
16. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Riaz N; Havel JJ; Makarov V; Desrichard A; Urba WJ; Sims JS; Hodi FS; Martín-Algarra S; Mandal R; Sharfman WH; Bhatia S; Hwu WJ; Gajewski TF; Slingluff CL; Chowell D; Kendall SM; Chang H; Shah R; Kuo F; Morris LGT; Sidhom JW; Schneck JP; Horak CE; Weinhold N; Chan TA
Cell; 2017 Nov; 171(4):934-949.e16. PubMed ID: 29033130
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.
Rudqvist NP; Pilones KA; Lhuillier C; Wennerberg E; Sidhom JW; Emerson RO; Robins HS; Schneck J; Formenti SC; Demaria S
Cancer Immunol Res; 2018 Feb; 6(2):139-150. PubMed ID: 29180535
[TBL] [Abstract][Full Text] [Related]
18. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
Front Immunol; 2017; 8():1367. PubMed ID: 29104575
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
20. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8
Naing A; Infante JR; Papadopoulos KP; Chan IH; Shen C; Ratti NP; Rojo B; Autio KA; Wong DJ; Patel MR; Ott PA; Falchook GS; Pant S; Hung A; Pekarek KL; Wu V; Adamow M; McCauley S; Mumm JB; Wong P; Van Vlasselaer P; Leveque J; Tannir NM; Oft M
Cancer Cell; 2018 Nov; 34(5):775-791.e3. PubMed ID: 30423297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
